Metastatic Prostate Cancer Research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition

Follow-on analysis of results from the phase 3 PSMAfore study, along with the overall study results, support the consideration of 177Lu-PSMA-617 as a new standard treatment approach for this prevalent population of patients with mCRPC. Research led by Dana-Farber Cancer Institute and others.